Insiders · PLX

PLX insider transactions

Protalix BioTherapeutics Inc. (DE) (PLX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for PLX

• 36d
  Amendment: New insider Mamlok Gilad claimed ownership of 3,631 shares (SEC Form 3)

  3/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 162d
  PRESIDENT AND CEO Bashan Dror bought $101,360 worth of shares (56,000 units at $1.81), increasing direct ownership by 42% to 188,516 units (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 195d
  Director Bar-Shalev Amos sold $314 worth of shares (168 units at $1.87), closing all direct ownership in the company (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Forster Eliot was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Boudes Pol F was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Schwartz Aharon was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Melincoff Gwen A was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Bar-Shalev Amos was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Elze Christian was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Sr. VP, Operations Naos Yaron was granted 25,000 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  Director Ben Zvi Shmuel was granted 7,500 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 271d
  PRESIDENT AND CEO Bashan Dror was granted 195,000 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 282d
  SEC Form 3 filed by new insider Mamlok Gilad

  3 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 295d
  Director Schwartz Aharon bought $205,884 worth of shares (129,000 units at $1.60), increasing direct ownership by 74% to 303,000 units (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 335d
  SEC Form 3 filed by new insider Elze Christian

  3 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 574d
  Amendment: Sr. VP and CFO Rubin Eyal was granted 90,909 shares (SEC Form 4)

  4/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 616d
  SEC Form 4 filed by Sr. VP, Operations Naos Yaron

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 616d
  Sr. VP and CFO Rubin Eyal was granted 99,010 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 790d
  Bashan Dror was granted 263,960 shares (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 957d
  Bashan Dror bought $90,484 worth of shares (64,516 units at $1.40), increasing direct ownership by 95% to 132,516 units (SEC Form 4)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 973d
  SEC Form 4 filed by Boudes Pol F

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 973d
  SEC Form 4 filed by Schwartz Aharon

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 973d
  SEC Form 4 filed by Ben Zvi Shmuel

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 973d
  SEC Form 4 filed by Melincoff Gwen A

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 973d
  SEC Form 4 filed by Bar-Shalev Amos

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 991d
  SEC Form 4 filed by Forster Eliot

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 991d
  SEC Form 3 filed by new insider Forster Eliot

  3 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1021d
  SEC Form 4: Bashan Dror was granted 800,000 shares

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1021d
  SEC Form 4: Hayon Yael was granted 35,115 shares

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1021d
  SEC Form 4: Rubin Eyal was granted 201,903 shares

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1021d
  SEC Form 4: Naos Yaron was granted 187,344 shares

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1244d
  SEC Form 4: Schwartz Aharon bought $155,815 worth of shares (110,000 units at $1.42), increasing direct ownership by 172% to 174,000 units

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Naos Yaron

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Ben Zvi Shmuel

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Hayon Yael

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Bashan Dror

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Rubin Eyal

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Schwartz Aharon

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Bronfeld Zeev

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Bar-Shalev Amos

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Melincoff Gwen A

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1362d
  SEC Form 4 filed by Boudes Pol F

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1429d
  SEC Form 4 filed by Ben Zvi Shmuel

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1429d
  SEC Form 3 filed by new insider Ben Zvi Shmuel

  3 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1512d
  SEC Form 4: Bashan Dror bought $102,000 worth of shares (68,000 units at $1.50)

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1555d
  SEC Form 4: Bashan Dror was granted 637,531 shares

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1825d
  SEC Form 4 filed by Protalix BioTherapeutics, Inc.

  4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
• 1933d
  SEC Form 3: Ltd. Technologies Pharma Dexcel claimed ownership of 4,556,031 units of Common Stock

  3 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)